Jazz sells sleep and cancer medicines including Xywav.
Jazz Pharmaceuticals plc (JAZZ) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 16:07 ET. Consensus EPS estimate is $6.47.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-03 | FY2026 Q2 | $6.18 | $5.71 | -7.6% | $1.21B |
| 2026-05-05 | FY2026 Q1 | $4.64 | $6.34 | +36.6% | $1.07B |
| 2026-02-24 | FY2025 Q4 | $6.52 | $6.64 | +1.8% | $1.20B |
| 2025-11-05 | FY2025 Q3 | $5.95 | $8.13 | +36.6% | $1.13B |
| 2025-08-05 | FY2025 Q2 | $-6.12 | $-8.25 | -34.8% | $1.05B |
| 2025-05-06 | FY2025 Q1 | $4.51 | $1.68 | -62.7% | $897.84M |
| 2025-02-25 | FY2024 Q4 | $5.83 | $6.60 | +13.2% | $1.09B |
| 2024-11-06 | FY2024 Q3 | $5.47 | $6.61 | +20.8% | $1.05B |
JAZZ has beaten consensus EPS in 5 of its last 8 reported quarters.
Highlights from JAZZ's Aug 3 report: EPS of $5.71 — a miss vs the $6.18 estimate (-8%); revenue of $1.21B — a beat vs the $1.11B consensus (+8%). Focus now shifts to oncology growth and Epidiolex.
See JAZZ on the live calendar →